Biomedical subjects
Publications and source records attributed to M F Scanlon.
A solitary intrasellar plasmacytoma with marked pituitary fossa destruction and yet near normal pituitary gland function is described. We suggest that a minimal disturbance of endocrine function together with a radiologically abnormal pituitary fossa indicates that the primary lesion may lie outside the pituitary fossa.
Anterior pituitary cells from euthyroid and hypothyroid male rats have been cultured as monolayers for 3 days with or without 5 nM T3 and stimulated with either human pancreatic GH-releasing factor 1-40 (hpGRF), TRH, or the Ca2+ channel ionophore A23187. Basal GH secretion was reduced in the hypothyroid cultures (P less than 0.001) and basal TSH secretion increased (P less than 0.001). Culture with T3 increased GH secretion and intracellular GH content in euthyroid and hypothyroid cultures but suppressed TSH secretion with no effect on intracellular TSH content in either euthyroid or hypothyroid cultures. hpGRF released more GH from euthyroid [3.52 +/- 0.2 (SE) micrograms/6 h X 10(5) cells] than hypothyroid cultures of (0.17 +/- 0.01 micrograms/6 h X 10(5) cells, P less than 0.001) without a change in ED50 (approximately 0.02 nM). The reduction in hpGRF-induced GH release remained significant when corrected for the reduced intracellular GH content in the hypothyroid cultures. hpGRF-induced GH release also declined relative to A23187-induced GH release in hypothyroid cultures. Culture with 5 nM T3 doubled maximum hpGRF-induced GH release in euthyroid cultures and increased maximum release 10-fold in hypothyroid cultures without altering the ED50 of hpGRF action. In contrast, T3 suppressed TRH-induced TSH release in euthyroid cultures but was without effect on TRH-induced TSH release in the hypothyroid cultures. T3 did not effect the ED50 of TRH action (2-5 nM). In summary, hypothyroid rat anterior pituitary cells in culture have a reduced maximal GH response to hpGRF, but the same ED50. hpGRF activity can be partially restored by physiological concentrations of T3 in vitro.
TSH responses to adrenergic agonists have been measured in 3-day monolayer cultures of euthyroid and hypothyroid male rat anterior pituitary (AP) cells. Responses were qualitatively similar in that (-)epinephrine and (-)norepinephrine had the same ED50 in each culture (ED50 = approximately 6 and 16 nM, respectively) and demonstrated the same alpha 1-adrenergic specificity. Hypothyroid cultures secreted approximately twice as much TSH per cell as euthyroid cultures over the 2-h experimental period. (-)Epinephrine produced a 95 +/- 8% (mean +/- SE) release of TSH relative to basal secretion in euthyroid cultures and only 62 +/- 7% release in the hypothyroid cultures (P less than 0.01). The comparable figures for (-)norepinephrine were 62 +/- 7% and 38 +/- 5%, respectively (P less than 0.05). In absolute terms, adrenergic agonists released the same amount of TSH from euthyroid and hypothyroid cultures. In contrast, TRH (and the Ca+2 channel ionophore A23187) released twice as much TSH from the hypothyroid cells as in the euthyroid cultures. Epinephrine-induced TSH release was significantly impaired (P less than 0.001) when either euthyroid or hypothyroid cells were cultured without thyroid hormones. In contrast, TRH-induced TSH release was enhanced (P less than 0.001) in the euthyroid cultures. [3H]Dihydroergocryptine [( 3H]DHE) was used to quantify alpha 1-adrenoreceptors on the same cell preparations as those used to derive the functional data (see above). Prazosin (1 microM) was used to define nonspecific binding of [3H]DHE. Specific binding to euthyroid cells had a Kd of 5.8 +/- 4 nM and a maximum binding capacity of 2.2 +/- 0.4 fmol/10(5) cells (n = 5). In parallel cultures of hypothyroid cells, the Kd (6.2 +/- 5 nM) was not significantly different, whereas the maximum binding capacity (1.4 +/- 0.3 fmol/10(5) cells) was significantly reduced (P less than 0.05). Adrenergic compounds showed a rank order of potency of prazosin greater than (-)epinephrine greater than or equal to (-)norepinephrine greater than or equal to yohimbine greater than clonidine against the binding of 5 nM [3H]DHE to euthyroid and hypothyroid cells. The amount of [3H]DHE binding per cell that each adrenergic compound was able to displace at saturating concentrations was less in hypothyroid cells than in euthyroid cells. There was no change in the ED50 values of these compounds in the same experiments.(ABSTRACT TRUNCATED AT 400 WORDS)
The ability of human pancreatic GH releasing factor 1-40 (hpGRF 1-40) to release GH has been studied in rat anterior pituitary cells in primary culture. Over 24 hours hpGRF (1-40) increased total (cell content and secretion) production 2-fold with an ED50 of 20 pM. Subsequent hpGRF (1-40) stimulation of GH release was not affected by pretreatment when the fall in stored GH was taken into account. In contrast LH responses to gonadotrophin releasing hormone (GnRH) were markedly desensitized after 24 hours GnRH pretreatment in the same experimental system and using the same analysis. hpGRF (1-40) responses were not desensitized when pretreatment was for 3, 12 or 24 hours. The data show that hpGRF (1-40) responses do not desensitize in our experimental conditions under which GnRH responses show marked desensitization.
Pituitary function was tested in predefined clinical groups of benign breast disease under strictly controlled clinical and laboratory conditions. Two different tests of prolactin storage and control mechanisms, direct stimulation by thyrotropin-releasing hormone (TRH) and inhibition of dopaminergic control by domperidone, indicate a significant abnormality in patients with severe cyclical mastalgia and nodular breast disease (P less than 0.05 and P less than 0.002), but not in those with noncyclical mastalgia. No abnormalities of thyroid function were found.
A generalized abnormality of hypothalamopituitary function was found in 17 patients with cyclical pronounced mastalgia compared with 11 controls by using a combined thyrotrophin releasing hormone and gonadotrophin releasing hormone test. The release of prolactin, luteinizing hormone and follicle stimulating hormone was significantly greater in cyclical mastalgia patients than in controls. Basal thyrotrophin, T3 and T4 levels were within the normal range in both groups indicating normal thyroid status in benign breast disease. The single measurement of oestrogen and progesterone in the luteal phase was not abnormal. These data demonstrate an alteration in lactotroph and gonadotroph function in patients with cyclical mastalgia. It is unknown at present whether this represents an appropriate cellular response to altered central or peripheral signals. There is no evidence to suggest, however, that the anterior pituitary cell types are abnormal per se.
Rat anterior pituitary cells have been maintained over an 18-day period in a perfusion system designed around artificial capillaries. Using novel methodology the cells have been visualized by light microscopy and appear as aggregates, closely attached to and sometimes stretching around the capillaries. Their morphology is consistent with previous histology at the level of light microscopy. The techniques described are compatible with immunohistochemistry and electron microscopy. The functional integrity of thyrotrophs and lactotrophs maintained in the system has been examined by measuring the dynamics of TSH and PRL secretion in response to depolarization, TRH and dopamine (DA). TSH and PRL were significantly and reproducibly released by TRH over a 7-day period. On each day the release was dose-dependent with a threshold of at least 28 pg. Qualitatively the responses were rapid in onset (within minutes) for both hormones. Similar responses were measured in response to high K+ depolarization. Basal secretion of TSH and PRL was rapidly and significantly inhibited by DA in a dose-dependent manner (ED50 20 +/- 25 nM for TSH and 70 +/- 40 nM for PRL). Inhibition was dependent on the continued presence of DA and could be mimicked by bromocriptine and stereospecifically prevented by the active but not the inactive isomer of the DA receptor antagonist butaclamol. Simultaneous administration of 10(-6) M DA with 10(-8) M TRH prevented the release of TSH and PRL. The effect of DA was transient, subsequent TRH responses being qualitatively and quantitatively normal.(ABSTRACT TRUNCATED AT 250 WORDS)
Epinephrine and TRH independently release TSH from rat anterior pituitary cells in primary monolayer culture (ED50, 11 and 5 nM, respectively; maximum responses, 80% and 110%, respectively). The effects of these compounds together are additive, even at concentrations at which each is maximally effective alone. Dopamine inhibited basal and epinephrine-stimulated TSH secretion by 25 +/- 5% (+/-SE; ED50, 50 +/- 9 nM in each case). Somatostatin was effective against epinephrine-stimulated, but not basal, TSH secretion (80 +/- 4% inhibition; ED50, 1 +/- 3 nM). The data show that epinephrine is a potential regulator of TSH secretion by its own action and via its interactions with TRH, dopamine, and somatostatin.
Monolayer cultures were prepared from the anterior pituitary (AP) lobes of normal male rats and male rats made hypothyroid by treatment with aminotriazole. After 3 days in culture, the cells from hypothyroid animals showed significantly greater TSH and PRL secretory activity and significantly less GH secretory activity than did parallel euthyroid cultures. The responses of euthyroid and hypothyroid cultures to dopaminergic agonists and antagonists were examined. Bromocriptine, apomorphine, and dopamine (DA) inhibited euthyroid TSH secretion by approximately 30%, whereas each drug inhibited hypothyroid TSH secretion by approximately 60% (P less than 0.01 for each drug). In contrast, the three agonists were less effective in inhibiting PRL secretion from hypothyroid cells (P less than 0.05 for each drug). The rank order of potency [bromocriptine greater than (+)butaclamol greater than apomorphine greater than DA greater than (-)butaclamol] shown against secretion was the same for TSH and PRL in both euthyroid and hypothyroid cell cultures and is typical of a DA receptor-mediated process. The binding of [3H]dihydroergocryptine (DHE) to DA receptors on euthyroid and hypothyroid cells was examined under the same conditions in which the secretory responses were determined. One micromolar concentration of (+)butaclamol was used to define nonspecific binding. Specific binding was saturable and stereospecific in each case. The rank order of potency of dopaminergic agonists and antagonists in competing for [3H] DHE binding was the same as that demonstrated against the secretion of TSH and PRL. Each compound displaced significantly more [3H]DHE from hypothyroid cells than from euthyroid cells (P less than 0.05 for each drug). Construction of adsorption isotherms for [3H]DHE binding to DA receptors on euthyroid and hypothyroid cells and subsequent Scatchard analysis revealed a 3- to 4-fold increase in receptor number without a significant change in affinity. Immunohistochemistry on AP lobes before and after dispersion revealed an increase in thyrotrophs and thyroidectomy cells in hypothyroid rats relative to those in control animals. In euthyroid animals thyrotrophs were 10.1% of the total AP cell population, in hypothyroid animals they plus the thyroidectomy cells were 36.3% of the total AP cells. Therefore, the increased number of DA receptors per lobe could be accounted for by increased numbers of thyrotrophs. The mechanism of the altered sensitivity to DA induced by hypothyroidism in lactotrophs and thyrotrophs remains to be clarified.
To investigate the hypothesis whether the hypothalamus releases an active (ouabain-sensitive) sodium transport inhibitor, we cultured hypothalamic and cortical cells from day 17 fetal rats. Culture media from hypothalamic cells reduced the total erythrocyte sodium efflux rate constant from 0.487 +/- (SE) 0.014 to 0.408 +/- 0.013 (P less than 0.001), and the ouabain-sensitive rate constant from 0.305 +/- 0.015 to 0.240 +/- 0.016 (P less than 0.01). Hypothalamic media also showed a dose-dependent displacement of [3H]-ouabain-binding to erythrocyte membranes. Neither cortical nor conditioned media (incubated without cells) had any effect. Various well-characterized hormones of hypothalamic origin failed to inhibit sodium efflux rate constant. These studies demonstrate that fetal rat hypothalamic cells contain and release a factor which inhibits sodium transport in human erythrocytes.
Explore the source record for details and available documents.
We have investigated the nature of the immunoreactive somatostatin (SS) and thyrotropin-releasing hormone (TRH) produced by long-term capillary perfusion cultures of rat fetal cortical and hypothalamic cells. Dispersed cortical and hypothalamic cells from 17-day-old fetal rats were injected on to the outer surfaces of separate capillary membrane perfusion systems. Recirculating nutrient medium (Minimum Essential Medium with added glucose, antibiotics and 10% fetal calf serum) was then perfused via the capillary lumen at a rate of 1.5 ml/min and was changed three times weekly. Medium reservoirs, gaseous exchange coils and capillary columns were maintained in a 95% air/5% CO2 environment with 100% humidity. After 6 and 12 days in continuous perfusion, both cortical and hypothalamic cells demonstrated immuno-reactive SS release following 60 mMK+ depolarization (5- to 7-fold increase from basal secretion levels of 15-20 pg/3 X 10(7) cells/10 min). This response was clearly calcium dependent since it was abolished during washes with Ca2+-free Krebs-Ringer bicarbonate solution. Affinity purified material from pooled neuronal perfusates showed three distinct peaks of somatotropin release-inhibiting factor (SRIF) immunoreactivity following polyacrylamide gel chromatography on Biogel-P10. The dominant form coeluted with synthetic tetradecapeptide-somatostatin (SS-14) and a smaller amount (c 30%) coeluted with synthetic SS-28. (The SS-14 antibody used showed equimolar cross reactivity with SS-28). A larger form of immunoreactive material was also detected with an apparent molecular weight of about 11,500 daltons. Hypothalamic and cortical perfusates produced similar electrophoretic patterns of immunoreactive SS (ISS).(ABSTRACT TRUNCATED AT 250 WORDS)
Dopamine (DA) and the dopaminergic agonists bromocriptine and apomorphine inhibit the secretion of TSH as well as that of PRL by rat anterior pituitary (AP) cells in monolayer culture. The order of potency of the drugs is the same for the inhibition of both hormones: bromocriptine ED50 = 0.006 nM against PRL and 0.017 nM against TSH; apomorphine ED50 = 2.9 and 4.8 nM, respectively, and DA, ED50 = 30 and 370 nM, respectively. The dopaminergic antagonists domperidone (DOM) and metoclopramide prevent the inhibition of TSH and PRL by 10(-6) M DA (IC50 = 0.012 and 0.32 nM for metoclopramide against PRL and TSH, respectively; similarly, IC50 = 0.01 and 0.61 nM for DOM). The action of butaclamol is shown to be stereospecific, in that the (+) isomer is 1000-fold more potent in reversing the inhibition of both TSH and PRL by 10(-6) M DA than the (-) isomer [IC50 = 1.1 and 7200 nM for the (+) and (-) isomers against PRL; similarly, 6.3 and 2600 nM against TSH]. The use of radioligand-binding techniques with tritiated DOM ([3H]DOM) and dihydroergocriptine ([3H]DHE) has demonstrated a high affinity dopaminergic binding site upon rat AP cells under the same conditions as the cell cultures used in the hormone secretion studies. Both ligands have been shown to label a site with high affinity (Kd = 1-2 nM) and low capacity (2-3 fmol/10(5) cells). At this site, dopaminergic agonists and antagonists compete with both radioligands and display a rank order of potency which is the same as that shown against TSH and PRL secretion and which is typically dopaminergic. For [3H]DHE: bromocriptine Ki (0.04 nM) greater than metoclopramide = DOM (0.07 nM) greater than (+)butaclamol (0.7 nM) greater than apomorphine (20 nM) greater than DA (700 nM) greater than (-)butaclamol (2000 nM). Similar data were derived using [3H]DOM. The high affinity site is saturable, has rapid association and dissociation rates, as determined for both radioligands used, and is temperature dependent. In contrast, both radioligands bind to a second binding site on the cells that is of lower affinity (Kd = 244 nM for [3H]DOM and 678 nM for [3H]DHE) and larger capacity (100 fmol/10(5) cells for both ligands). This second site is neither stereospecific nor, using the methodology presented here, does it discriminate between other dopaminergic compounds. It is thus not considered to represent specific DA receptor binding. It is concluded that the dopaminergic stimulus causing the inhibition of TSH and PRL secretion from rat AP cells in culture is mediated via a high affinity DA receptor present upon lactotrophs and thyrotrophs and that this receptor has similar characteristics on the two cell types.
An in vitro study of the alpha-adrenergic control of TSH secretion was carried out on rat anterior pituitary cells in monolayer culture. The ability of adrenergic agonists and antagonists to alter TSH release from the cells was determined. With the use of parallel cell cultures under the same conditions, alpha-adrenergic binding sites were measured and characterized with [3H]dihydroergocryptine (DHE) as the radioligand. Epinephrine (E) and norepinephrine (NE) released TSH over a 2-h period in a dose-dependent and stereospecific manner (ED50 = 1 and 700 nM for the (-) and (+/-) stereoisomers of E; 7 and 600 nM for the active and inactive stereoisomers of NE respectively). Maximum release was 3- to 4-fold greater than basal secretion for both isomers of E but less (2- to 3-fold) for the isomers of NE. Phenylephrine, an alpha 1-agonist, elicited a 2- to 3-fold increase in TSH secretion (ED50 = 13 nM). Clonidine, an alpha 2-agonist, produced only slight stimulation at concentrations greater than 10(-6) M, and isoproterenol was ineffective. Prazosin, an alpha 2-antagonist (IC50 = 0.12 nM), was 500-fold more effective than yohimbine, an alpha 2-antagonist (IC50 = 60 nM), in reversing the TSH stimulation induced by 10(-7) M E. With [3H]DHE and prazosin as competing ligands, alpha-adrenergic receptors could be quantified independently of dopamine receptors present upon the same mixed cell preparations. The kinetics of specific radioligand binding to the cells were rapid (k1 = 1.75 X 10(-7) M-1 min-1, k2 = 0.131 min-1), equilibrium being reached within 15 min at 22 C. Adsorption isotherms and Scatchard analysis revealed a single population of binding sites with high affinity (kd = 7.2 nM) and low capacity (3 fmol/10(5) cells). Competition by adrenergic agonists for [3H]DHE binding was stereospecific. The rank order of potency against binding was identical with that determined functionally against TSH secretion (Ki for prazosin, 0.7 nM greater than thymoxamine, 2.7 nM greater than (-) E, 7 nM greater than phentolamine, 8 nM greater than (-) NE, 11.5 nM greater than phenylephrine, 100 nM greater than yohimbine, 300 nM greater than clonidine, 4500 nM greater than (+/-) E, 5000 nM greater than (+/-) NE, 7000 nM greater than isoproterenol, 3 X 10(5) nM), and typical of binding to an alpha 1-adrenoreceptor. It is concluded that TSH can be specifically released from rat anterior pituitary cells in monolayer culture by the direct effects of adrenergic agonists and that the stimulation is mediated via a single high affinity population of alpha 1-adrenergic receptors.
In order to delineate more accurately the dopaminergic control of anterior pituitary function in normal subjects and in patients with pathological hyperprolactinemia, we investigated the nature of the circadian variation in the dopaminergic inhibition of TSH release in such subjects. Ten euthyroid women with hyperprolactinemia due to presumed PRL-secreting microadenomas (aged 18-60 yr) were compared with 11 normal, euthyroid women (aged 18-32 yr). Each received the dopamine receptor blocking drug domperidone (10 mg, iv) at 1100 and 2300 h (tests randomized and separated by at least 1 week). Blood was sampled 10, 20, 30, 45, and 60 min after drug administration. Normal women had a greater TSH response to domperidone and, hence, greater dopaminergic inhibition of TSH release at 2300 than at 1100 h (sum of TSH increments; mU/liter mean +/- SE, 8.5 +/- 1.3 vs. 4.8 +/- 0.5, P less than 0.01), whereas there was no difference in the dopaminergic inhibition of PRL release at each time of day. Hyperprolactinemic women also had a significantly greater TSH response to domperidone at 2300 than at 1100 h (42.0 +/- 10.2 vs. 19.1 +/- 2.8, P less than 0.001). The hyperprolactinemic women had a greater TSH response to domperidone than normal women at each time of day studied (1100 h, 19.1 +/- 2.8 vs. 4.8 +/- 0.5, P less than 0.001; 2300 h, 42.0 +/- 10.2 vs. 8.5 +/- 1.3, P less than 0.001). The incremental PRL responses to domperidone were significantly less in hyperprolactinemic than in normal women and did not differ at each time of day. In conclusion, the circadian change in the dopaminergic inhibition of TSH secretion is specific for TSH and not PRL. This indicates that the dopaminergic control of TSH and PRL secretion can be dissociated in normal subjects. Second, hyperprolactinemic women with presumed PRL-secreting microadenomas had qualitatively normal but quantitatively exaggerated circadian pattern of dopaminergic inhibition of TSH release. These data argue against a hypothalamic dopaminergic defect in hyperprolactinemia and support the view that the established dopaminergic defect in the inhibition of PRL release is related specifically to PRL control and may well be at the anterior pituitary level.
Explore the source record for details and available documents.
We have tested the hypothesis that physiological puerperal hyperprolactinaemia may be secondary to reduced hypothalamic dopaminergic inhibition of prolactin (PRL) release. Nine post-partum females with physiological hyperprolactinaemia (aged 19-40 years; mean basal PRL +/- SE, 2099 +/- 257 mU/1, range 1002-3762 mU/1) were studied and results compared with fourteen normoprolactinaemic females (basal PRL less than 400 mU/1; aged 18-36 years). Puerperal hyperprolactinaemic females showed a reduced TSH response to dopamine (DA) receptor blockade with metoclopramide (10 mg i.v.) compared with normal females over a 60-min period following drug administration (total incremental TSH change, mean +/- SE, mU/1; 0.5 +/- 0.3 v. 3.1 +/- 1.0 P less than 0.005). This finding of reduced dopaminergic inhibition of TSH release in females with physiological puerperal hyperprolactinaemia supports the view that an overall reduction in hypothalamic dopaminergic tone may contribute towards hyperprolactinaemia in post-partum women.
Prolactin-secreting pituitary adenomas have only recently been recognised as distinct entities, but probably represent the most frequent type of secreting pituitary adenomas. As they occur mainly in young women during the period of genital activity, and as therapeutic success depends on their being detected while they are still small, accent is currently being placed on early diagnosis and specific therapy. Early diagnosis depends mainly on the results of exploration of the neuro-endocrine factors of the hypothalamus-pituitary axis. Treatment, while dependent upon the attitudes of the different teams, has been transformed by the re-introduction of the trans-sphenoidal surgical approach, and the availability of bromocriptine, an orally active dopamine agonist. Their combined use has produced selective successful results in the treatment of microadenomas. Bromocriptine can reduce the size of large prolactin-secreting adenomas, and is probably a better choice than surgery because of the high failure rate of trans-sphenoid operations in the case of macroadenomas, Long-term results of these two therapeutic procedures have still to be evaluated.